Literature DB >> 3157649

Sequential degradation of heparan sulfate in the subendothelial extracellular matrix by highly metastatic lymphoma cells.

M Bar-Ner, M D Kramer, V Schirrmacher, R Ishai-Michaeli, Z Fuks, I Vlodavsky.   

Abstract

A highly metastatic variant (ESb) of a methylcholanthrene-induced T lymphoma elaborates a heparan sulfate (HS) degrading endoglycosidase (heparanase) to a much higher extent than its non-metastatic parental subline (Eb). Whereas a serum-free medium conditioned by either subline contained a trypsin-like serine protease, heparanase activity was detected only in the ESb-conditioned medium (CM). ESb CM was incubated with a naturally produced, sulfate-labelled subendothelial extracellular matrix (ECM) or with a soluble, high-MW labelled proteoglycan first released from the ECM by incubation with Eb CM or with the partially purified ESb protease. Sulfate labelled degradation products were analyzed by gel filtration on Sephrose 6B. The optimal pH for degradation of ECM-bound HS was 6.2 as compared to pH 5.2 for degradation of the soluble proteoglycan. Heparanase-mediated degradation of both ECM-bound and soluble HS was inhibited by heparin. Addition of either trypsin, plasmin or to a lower extent, the purified ESb protease, stimulated between 5- and 20-fold the ESb CM-mediated degradation of ECM-bound HS but had no effect on heparanase-mediated degradation of the soluble proteoglycan. This stimulation was inhibited in the presence of heparin or protease inhibitors. These results indicate that both a protease and heparanase are involved in the ESb-mediated degradation of ECM-bound HS and that one enzyme produces a more accessible substrate for the next enzyme. This sequential cleavage is characteristic of degradation of a multimolecular structure such as the subendothelial ECM and hence cannot be detected in studies with its isolated constituents.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3157649     DOI: 10.1002/ijc.2910350411

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  19 in total

1.  A rapid quantitative assay for the detection of mammalian heparanase activity.

Authors:  C Freeman; C R Parish
Journal:  Biochem J       Date:  1997-07-01       Impact factor: 3.857

2.  Marine-derived oligosaccharide sulfate (JG3) suppresses heparanase-driven cell adhesion events in heparanase over-expressing CHO-K1 cells.

Authors:  Qiu-Ning Li; Hai-Ying Liu; Xian-Liang Xin; Qiu-Ming Pan; Lu Wang; Jing Zhang; Qin Chen; Mei-Yu Geng; Jian Ding
Journal:  Acta Pharmacol Sin       Date:  2009-06-22       Impact factor: 6.150

3.  Cloned cytolytic T-effector cells and their malignant variants produce an extracellular matrix degrading trypsin-like serine proteinase.

Authors:  M M Simon; H G Simon; U Fruth; J Epplen; H K Müller-Hermelink; M D Kramer
Journal:  Immunology       Date:  1987-02       Impact factor: 7.397

4.  Subendothelial extracellular-matrix heparan sulfate proteoglycan-degrading activity of human monocyte macrophages.

Authors:  K Shimada; T Ozawa
Journal:  Heart Vessels       Date:  1987       Impact factor: 2.037

5.  Degradation of heparin proteoglycan in cultured mouse mastocytoma cells.

Authors:  K G Jacobsson; U Lindahl
Journal:  Biochem J       Date:  1987-09-01       Impact factor: 3.857

6.  Protamine and protamine-insulins exacerbate the vascular response to injury.

Authors:  E R Edelman; L A Pukac; M J Karnovsky
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

Review 7.  Tumorigenic and adhesive properties of heparanase.

Authors:  Flonia Levy-Adam; Neta Ilan; Israel Vlodavsky
Journal:  Semin Cancer Biol       Date:  2010-07-07       Impact factor: 15.707

8.  Heparin modulates the composition of the extracellular matrix domain surrounding arterial smooth muscle cells.

Authors:  A D Snow; R P Bolender; T N Wight; A W Clowes
Journal:  Am J Pathol       Date:  1990-08       Impact factor: 4.307

9.  Human mononuclear cells contain an endoglycosidase specific for heparan sulphate glycosaminoglycan demonstrable with the use of a specific solid-phase metabolically radiolabelled substrate.

Authors:  R F Sewell; P E Brenchley; N P Mallick
Journal:  Biochem J       Date:  1989-12-15       Impact factor: 3.857

10.  Heparanase levels are elevated in the plasma of pediatric cancer patients and correlate with response to anticancer treatment.

Authors:  Itay Shafat; Ayelet Ben Barak; Sergey Postovsky; Ronit Elhasid; Neta Ilan; Israel Vlodavsky; Miriam Weyl Ben Arush
Journal:  Neoplasia       Date:  2007-11       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.